Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma

[1] Enoch J(2019)Evaluating whether sight is the most valued sense JAMA Ophthalmol 137 1317-1320

[2] McDonald L(1998)The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma Am J Ophthalmol 126 498-505

[3] Jones L(1998)Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures Am J Ophthalmol 126 487-497

[4] Jones PR(2005)The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage Prog Retin Eye Res 24 39-73

[5] Crabb DP(2002)The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma Arch Ophthalmol 120 701-713

[6] Burgoyne CF(2005)Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension J Ocul Pharmacol Ther 21 337-348

[7] Downs JC(2006)Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs. monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial Arch Ophthalmol 124 1230-1238

[8] Bellezza AJ(2010)The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension J Glaucoma 19 424-426

[9] Suh JK(2013)Fixed-combination brinzolamide 1%/brimonidine 0.2% vs. monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies Eye (Lond) 27 841-847

[10] Hart RT(2008)Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension J Glaucoma 17 211-216

[1] Enoch J(2019)Evaluating whether sight is the most valued sense JAMA Ophthalmol 137 1317-1320

[2] McDonald L(1998)The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma Am J Ophthalmol 126 498-505

[3] Jones L(1998)Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures Am J Ophthalmol 126 487-497

[4] Jones PR(2005)The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage Prog Retin Eye Res 24 39-73

[5] Crabb DP(2002)The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma Arch Ophthalmol 120 701-713

[6] Burgoyne CF(2005)Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension J Ocul Pharmacol Ther 21 337-348

[7] Downs JC(2006)Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs. monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial Arch Ophthalmol 124 1230-1238

[8] Bellezza AJ(2010)The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension J Glaucoma 19 424-426

[9] Suh JK(2013)Fixed-combination brinzolamide 1%/brimonidine 0.2% vs. monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies Eye (Lond) 27 841-847

[10] Hart RT(2008)Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension J Glaucoma 17 211-216